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We have developed the world's first novel type of 
artificial retina, OUReP (Okayama University Retinal 
Prosthesis), in which a photoelectric dye that converts 
light energy into electric potential is covalently bonded 
to the surface of a polyethylene thin film as an 
insulator. The receptor that absorbs light and the 
output device that generates displacement current to 
stimulate nearby neurons are integrated in a sheet of 
thin film. It has become possible to measure the 
surface potential of the artificial retina OUReP using a 
Kelvin probe that measures the surface potential of 
semiconductors. When light is turned on and off to the 
artificial retina OUReP, the surface potential changes 
rapidly. As the light intensity is increased, the potential 
change on the surface of the artificial retina becomes 
larger. As for safety, the artificial retina OUReP was 
not toxic in all tests for biological evaluation of 
medical devices. As for efficacy, the artificial retina 
OUReP was implanted under the retina by vitreous 
surgery in monkey eyes which had chemically-
induced macular degeneration with photoreceptor cell 
loss. Over the next 6 months, retinal detachment did 
not occur during the course, and the artificial retina 
was in contact with the retinal tissue. The amplitude of 
the visual evoked potential attenuated by macular 
degeneration recovered 1 month after implantation of 
the artificial retina, and the recovery of amplitude was 
maintained until 6 months after the implantation. By 
using multielectrode array-mounted dish recording 
system, it has been proved that action potential spikes 
are induced when the artificial retina is placed on 
degenerative retinal tissue of retinal dystrophic rats or  
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mice and exposed to light, which is used as an index 
of the effectiveness of the artificial retina. We have 
established manufacturing and quality control of the 
device in a clean room facility, proved the safety and 
efficacy, and are preparing for first-in-human 
investigator-initiated clinical trials. 
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1. Introduction 
We can roughly grasp objects and 
avoid obstacles to move around because 
we have a wide field of view which has, 
though, low resolution of visual acuity of 
about 0.1 in decimals, corresponding to 
20/200. The high-resolution retinal 
region with visual acuity of 1.0 in 
decimals, corresponding to 20/20, is only 
confined to a very narrow area of the 
retinal center, called the fovea centralis 
of the macula. Indeed, when we have 
visual acuity of 0.1 (20/200), we can read 
characters by enlarging them on a tablet 
personal computer with a camera, for 
instance, iPad. These lines of evidence 
suggest that wider visual field with 
visual acuity at the level of 0.1 would be 
set as the functional goal for vision in 
general as the minimal requirement. 
The beginning of vision is the 
photoreceptor cells in the retina in the 
eyeball, which convert light energy into 
cell membrane potentials and propagate 
the signals to the brain via relays of 
nerve cells (neurons). Diseases in which 
these photoreceptor cells die include 
retinitis pigmentosa in the category of 
congenital diseases and age-related 
macular degeneration in the category of 
acquired diseases. Although the 
photoreceptor cells are dead in these 
diseases, there are still surviving nerve 
cells (retinal ganglion cells) in the 
degenerated retinal tissue that formulate 
the optic nerve as their axons and 
connect to the brain. In the basic concept 
of artificial retina, an artificial substance 
that converts light into electrical signals 
stimulates the nerve cells that connect to 
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2. Artificial retina with electrode 
array system on the market 
For the first time in 2013, the Food 
and Drug Administration (FDA) in the 
United States approved an artificial 
retina called Argus II as a medical device 
for the manufacture and sale.1 In the 
system, an electrode array that combines 
60 electrodes are implanted in the eye, 
image information from an external 
camera with eyeglasses is processed, and 
electric currents are outputted to 
stimulate the retina. In Europe and the 
United States, it has since been sold at a 
price of about $150,000, and more than 
200 patients who have lost their eyesight 
due to retinitis pigmentosa have 
undergone the implant surgery. By 
implanting the artificial retina, it became 
possible for patients to understand the 
rough movements, and it was confirmed 
that the therapeutic concept of the 
artificial retina is clinically applicable. In 
this Argus II system, when an aggregate 
(array) of 60 electrodes with each 
diameter of 1 mm is fixed to the surface 
of the retina and an electric current is 
conducted from each electrode, the nerve 
fiber layer running from the periphery on 
the surface of the retina is first stimulated. 
The retinal ganglion cell layer beyond 
the nerve fiber layer is also stimulated at 
the same time. In this way, it is surprising 
that the vision of hand movement can be 
restored even by vertical and horizontal 
diffusion of electric charge injection 
which is outputted from the 6 x 10 mm 
square electrode array, indicating that the 
processing mechanism of the brain 
related to vision has great adaptability.  
In order to improve the visual 
quality of the artificial retina, it is first 
necessary to bring a large-area artificial 
retina into contact with the back of the 
retina (under the retina) in order to obtain 
a wide field of view. The artificial retina 
installed upon the surface of the retina on 
the vitreous side stimulates the nerve 
fiber layer running from the peripheral 
retina which is different from the retinal 
region with the point of stimulation as in 
the Argus II electrode array system. In 
contrast, the artificial retina installed 
under the retina is in direct contact with 
the retinal nerve cells and thus only 
nerve cells in the retinal region can be 
stimulated. Secondly, in order to increase 
the resolution, it is necessary to reduce 
the individual pixel area and increase the 
number of pixels. As long as electrodes 
and photodiodes are used as elements, it 
is considered difficult to achieve these 
two goals (artificial retina with a large 
number of pixels and a large area) at the 
same time. 
 
3. Photoelectric dye molecules as a 
key element of the device 
To think of the artificial retina 
simply, it can be said that elements that 
convert light into electrical signals are 
arranged in a plane to stimulate nerve 
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cells in the adjacent retina. As an 
element of the artificial retina that is 
neither an electrode nor a photodiode, we 
have arrived at photoelectric dye 
molecules that convert light energy into 
electric potential in the repertoire 
manufactured by Hayashibara Co., Ltd. 
(Nagase & Co. Ltd) in Japan. The 
photoelectric dyes have been originally 
produced for dye-sensitized solar cells. 
We selected a photoelectric dye that has 
stable molecular structure and has 
absorption wavelength in the visible 
light (Fig. 1), verified that the 
photoelectric dye stimulates nerve cells 
under light exposure,2 and applied for a 
patent in 2002. A US patent was granted 
in 2006,3 a Japanese patent was granted 
in 2012, and both patents were 
transferred to Okayama University in 
2014. In 2018, a US patent on the 
manufacturing was also granted.4 
 
 
Fig. 1. Chemical process to produce photoelectric dye-coupled polyethylene thin film as artificial 
retina OUReP. Carboxyl group (COOH) is induced on polyethylene thin film surface by fuming 
nitric acid treatment (A), ethylene diamine is coupled to carboxyl group on the film surface (B), 
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4. Polyethylene thin film as a basal 
component of the device 
We encountered a polyethylene 
thin film as a soft and stable film that 
binds photoelectric dye molecules. 
Polyethylene is also implanted in the 
living body as a component of an 
artificial joint, and it is considered that 
there is no problem in in-vivo stability 
and biocompatibility. The surface of the 
polyethylene thin film was treated by 
fuming nitric acid to introduce a 
carboxyl (COOH) group, and the 
candidate photoelectric dye (NK-5962) 
was covalently bonded via the reactive 
group (Fig. 1) to establish the prototype 
of the artificial retina, OUReP (Okayama 
University Retinal Prosthesis).5-7 Using 
this prototype, we investigated the 
response in cultured neurons and in the 
isolated retinal tissues,6,7 and 
demonstrated visual recovery by 
implanting it under the retina of the eyes 
in hereditary retinal dystrophic rats (RCS 
rats).8-11 In RCS rat studies, plain 
polyethylene films with no photoelectric 
dye-coupling were implanted under the 
retina in the eyeball as controls. 
Compared with control RCS rats, RCS 
rats with OUReP implantation under the 
retina in the eyeball showed better vision 
in behavior tests, and better 
electrophysiological response in the 
retina and in the brain, as revealed by 
electroretinography and visual evoked 
potential, respectively.8-11 
In parallel, the properties of the 
polyethylene thin film surface were 
changed so as not to cause glial foreign 
body reaction,12 and further 
improvements were made to bond 
photoelectric dye molecules to the 
polyethylene thin film surface at high 
density. The feature of this artificial 
retina is that the photoelectric dye is 
bonded to both sides of the polyethylene 
thin film which is an insulator, and the 
receptor that absorbs light and the output 
device that generates electric potential 
are integrated in a sheet of thin film. 
Therefore, other parts such as an external 
electric battery are not required. 
 
5. Kelvin probe to measure surface 
electric potential changes 
At the initiative by Kenichi 
Takarabe, in Faculty of Science, 
Okayama University of Science, a 
semiconductor expert who presides over 
"Semiconductor Net Okayama," it has 
become possible to measure the surface 
potential of the artificial retina OUReP 
using a Kelvin probe that measures the 
surface potential of semiconductors (Fig. 
2).13 When light is turned on and off to 
the artificial retina OUReP, the surface 
potential changes rapidly. As the light 
intensity is increased, the potential 
change on the surface of the artificial 
retina becomes larger (Fig. 2). At the 
brightness of the room light of 100 to 
200 lux, the potential of the artificial 
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retina surface is induced to change by 100 to 200 mV.14 
 
 
Fig. 2. Kelvin probe measurement of surface electric potential changes on artificial retina OUReP. 
Surface electric potential changes become larger in response to increase of light intensity (A), are 
induced by visible light wavelength (B), and without time lag (C).  
 
6. Basic principle of photoelectric 
dye-based retinal prosthesis 
Electrically stimulating devices 
have been widely used in human body 
for many years: for instance, a heart 
pacemaker to stimulate 
cardiomyocytes,15 and neurostimulators 
for vagus nerve stimulation in epilepsy 
and deep brain stimulation in Parkinson 
disease.16,17 All devices output 
conduction current of electron charges 
which flows out from direct current (DC) 
electric battery attached to devices. 
Displacement current is another type of 
electric current. The displacement 
current is generated in electric battery 
which consists of capacitor and electric 
generator with temporal dependence of 
electric flux. The displacement current 
which is generated in this type of electric 
battery induces, outside the battery, the 
electric current into the electric 
conductive medium attached to this 
battery. This electric current, outside the 
battery, is also called as the displacement 
current. For instance, the pyroelectric 
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sensor, which detects infrared light, 
operates with the displacement current 
mode and is commercially 
distributed.18,19 Capacitive current has 
basically the same definition as the 
displacement current, and has been 
applied to devices for neural-prosthetic 
interface such as BIONTM (BIOnic 
Neuron) system.20 
Until now, no device to output 
displacement current or capacitive 
current is at clinical use in human body. 
We have designed photoelectric dye-
coupled thin film (OUReP) to output 
electric potential probably as 
displacement current in response to 
light.13,14 A similar attempt to use the 
photoelectric dye to stimulate neuronal 
cells was done by the other group of 
researchers.21 
 
7. Biological safety tests for a medical 
device 
In the process when we 
investigated that this photoelectric dye 
(NK-5962) was not toxic, we also found 
that it had the effect of suppressing nerve 
cell death, namely preventing neuronal 
apoptosis.22,23 In March 2012, the 
Ministry of Health, Labor and Welfare's 
Pharmaceutical and Food Safety Bureau 
in Japan published “the guidelines for 
biological safety evaluation necessary 
for application for manufacturing and 
marketing approval of medical devices", 
leading to common recognition 
regarding the safety evaluation of 
medical devices in Japan. It is based on 
ISO 10993 “Biological evaluation of 
medical devices”. The artificial retina 
OUReP was not toxic in cytotoxicity test, 
skin sensitization test, genetic toxicity 
tests (bacterial reverse mutation test, 
human chromosomal aberration test), 
implantation test, eye irritation test, 
acute and repeated-dose systemic 
toxicity tests. In addition, the 
photoelectric dye itself, which is a key 
element of the artificial retina, was not 
toxic in all of these tests. 
 
8. Clean room facility for 
manufacture and quality control 
In December 2014, Minori 
Industry Co., Ltd., a small and medium-
sized manufacturing company in a 
different specialty of industry in 
Okayama Prefecture, Japan, signed a 
joint research agreement with Okayama 
University regarding basic 
manufacturing technology for the 
artificial retina. In January 2015, we rent 
an office space at the Okayama 
University Incubator operated by the 
Organization for Small & Medium 
Enterprises and Regional Innovation, an 
affiliated organization of the Ministry of 
Economy, Trade and Industry in Japan, 
and in May, built a clean room 
manufacturing facility (Fig. 3). In March 
2016, Minori Industry Co., Ltd. 
registered the medical device 
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manufacturing industry in Okayama 
Prefecture at this manufacturing site. 
Tetsuya Uchida as a collaborating 
scientist, will be in charge of the clinical 
trial device manufactured under the 
quality management system (QMS), and 
the device will be provided for a first-in-
human investigator-initiated clinical trial 




Fig. 3. Clean room facility for manufacturing of artificial retina OUReP. Ceiling and walls of 
clean room are made by transparent acrylic boards (A). Polyethylene thin film is produced by 
mold in vacuum pressurizer (B), treated with fuming nitric acid to induce surface carboxyl group 
(C), and chemically coupled with ethylene diamine and then with photoelectric dye (D). 
  
9. Preclinical animal tests for safety 
and efficacy 
In dogs and rabbits, the artificial 
retina OUReP was implanted under the 
retina in the eyeball in the same manner 
as in human vitreous surgery, and the 
safety of the surgery was evaluated.24,25 
In monkeys, cobalt chloride solution was 
injected under the retina of the right eye 
to create chemically induced macular 
degeneration with photoreceptor cell 
loss, and the artificial retina OUReP was 
implanted under the retina by vitreous 
surgery.26 Over the next 6 months, the 
condition of the retina was observed with 
optical coherence tomography (OCT), 
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and in addition, the visual evoked 
potential (VEP), which is the electrical 
activity of the occipital lobe induced by 
light flashing in front of the eye, was 
recorded. As a safety index, retinal 
detachment did not occur during the 
course, and the artificial retina was in 
contact with the retinal tissue. As an 
index of efficacy, the amplitude of the 
visual evoked potential attenuated by 
macular degeneration recovered 1 month 
after implantation of the artificial retina, 
and the recovery of amplitude was 
maintained until 6 months after the 
implantation (Fig. 4).26  
 
Fig. 4. Artificial retina OUReP implantation in monkey eye with chemically (cobalt chloride) 
induced macular degeneration. Note retinal attachment by optical coherence tomography (OCT) 
and visual evoked potential (VEP) amplitude recovery for 6 months. Modified from reference 26. 
 
In the dog,24 rabbit,25 and monkey 
tests,26 the artificial retina OUReP was 
inserted by grasping the artificial retina 
with tweezers (vitreous forceps) and 
carrying it under the retina, but it was 
difficult to perform each step as a 
surgical procedure. Therefore, we 
developed the OUReP Injector, a 
disposable injector that rolls the artificial 
retina and pushes it under the retina (Fig. 
5, Fig. 6).27,28 The latest injector is made 
of polypropylene with a curved tip tube 
with an inner diameter of 1.4 mm and a 
wall thickness of 0.1 mm, and is 
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manufactured by Minori Industry Co., 
Ltd. using a straw manufactured by 
Shibase Co., Ltd., in Okayama, Japan 
(Fig. 5, Fig. 6).28 
 
 
Fig. 5. Disposable OUReP Injector. Schematic drawing of surgical procedures (top) and latest 
models of OUReP Injector (bottom). 
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Fig. 6. Vitreous surgery images to implant artificial retina OUReP by OUReP Injector in a rabbit 
eye. After vitreous gel is cut (A), retinal detachment is induced by subretinal injection of fluid 
with 38-gauge tip (B), and a retinal tear is made by coagulation with diathermy (C). OUReP 
Injector is inserted into vitreous through scleral incision (D), and advanced to the retinal tear (E). 
OUReP is pushed out into the subretinal space (F). Fluid in vitreous is changed to air, subretinal 
fluid is aspirated (G), and laser is applied around the tear (H). Modified from reference 28. 
 
10. Action potential spike induced in 
dystrophic retinal tissues by 
OUReP 
Strains that develop hereditary 
retinal degeneration (dystrophy) are 
maintained and marketed in rats14 and 
mice.29 In the experimental procedure 
when normal retinal tissue of rats and 
mice is removed from the eyeball and 
placed on a petri dish (multi-electrode 
petri dish) in which electrodes are 
embedded and exposed to light, a light-
evoked action potential spike, which is 
the activity of nerve cells in the retinal 
tissue, is recorded. In contrast, light-
evoked action potential spikes do not 
occur when degenerative retinal tissue is 
removed from the eyeball of retinal 
dystrophic rats or mice, placed in a 
multi-electrode petri dish and exposed to 
light. It has been proved that action 
potential spikes are induced when the 
artificial retina OUReP is placed on 
degenerative retinal tissue and exposed 
Internal Medicine Review  
  Photoelectric dye-based retinal prosthesis (OUReP) as a novel type 




Copyright 2020 Internal Medicine Review. All Rights Reserved. Volume 7, Issue 1. 
to light, which is used as an index of the 
effectiveness of the artificial retina (Fig. 
7).14,29 
 
Fig. 7. Action potential spike recording in degenerative retinal tissue of mice by multielectrode 
array dish. Dish bottom has 64 electrodes (A). Degenerative retinal tissue isolated from eyes of 
rd1 mice at the age of 8 weeks is placed on multielectrode array (B), and artificial retina OUReP 
with platinum weight at top is layered upon the retinal tissue (C). Multielectrode array dish (E) is 
placed on the stage of dissecting microscope with light source at bottom (D). Plain film with no 
dye coupling as control is first layered on the retinal tissue and then dye-coupled film as artificial 
retina OUReP is layered (F). Modified from reference 29.  
 
11. Investigator-initiated clinical trial 
in consultation with PMDA 
A consultation system to support 
from the beginning the development of 
pharmaceuticals and medical devices for 
venture companies and universities has 
started in 2011 as Pharmaceutical Affairs 
Strategic Consultation (renamed to 
Regulatory Science (RS) Strategic 
Consultation from 2017) at the 
Pharmaceuticals and Medical Devices 
Agency (PMDA) in Japan. On January 
11, 2013, we attended a PMDA interview 
for the first time and learned that an 
investigator-initiated clinical trial can be 
conducted for academia-produced 
devices that are not manufactured by 
companies. We have been consulting 
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with PMDA at the aim of conducting 
clinical trials led by investigators. In the 
plan of a first-in-human investigator-
initiated clinical trial, six patients with 
retinitis pigmentosa will be treated with 
implant surgery (Fig. 5, Fig. 6). The 
visual acuity of the eye with implant 
surgery will be at the level of light 
perception, and the visual acuity of the 
other eye was at the level of hand 
movement or light perception. The 
inclusion criteria are that there remains 
retinal layer structure to connect to the 
brain as revealed by optical coherence 
tomography (Table 1).30,31 
 
Table 1. Inclusion and exclusion criteria in the first-in-human clinical trial for OUReP 
Inclusion criteria 
1. Have the diagnosis of retinitis pigmentosa 
2. Have best-corrected visual acuity of light perception in the operated-on eye 
3. Have best-corrected visual acuity of hand movement or light perception in the fellow eye 
4. Have two retinal layers (nerve fiber layer and inner plexiform layer) preserved in the 
operated-on eye demonstrated by optical coherence tomography (OCT) 
5. At the age of 70 years or older 
6. Provide written consent to join the trial 
7. Will attend at follow-up examinations 
Exclusion criteria 
1. Have other eye diseases of glaucoma, optic nerve atrophy, or corneal opacity 
2. Have the history of retinal detachment in the operated-on eye. 
3. Have dense cataract which prevents fundus visualization 
4. Have undergone cataract surgery within 2 weeks 
5. Have drug allergy 
6. Have systemically poor condition with cancer, chemotherapy, or immunosuppresants 
7. Have severe hepatic, renal, cardiac, pulmonary, hematological, metabolic, or mental 
illness 
8. Currently join other trials 
 
12. Conclusions 
The artificial retina OUReP is the 
world's first novel medical device 
composed of organic molecules as a key 
element. Since there are no precedents, 
we are formulating our own 
manufacturing and quality standards to 
prepare for ethical and scientific clinical 
trials. In Japan, the Pharmaceutical 
Affairs Act was amended in 2013, and 
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the name of the law was changed to "The 
Act on Securing Quality, Effectiveness, 
and Safety of Pharmaceuticals, Medical 
Devices, etc." and came into effect in 
2014. Toward a clinical trial in which the 
artificial retina OUReP (class 3 medical 
device) is implanted using a disposable 
injector OUReP Injector (class 2 medical 
device), we are advancing 
manufacturing process control and 
quality control to create a clinical trial 
device outline and are implementing a 
clinical trial plan. We have a schedule to 
submit a notification of the plan to 
PMDA. The patients’ wish and safety are 
the first priority, and we are working in 
collaboration with the patients’ 
association. With the support of many 
people, we have finally reached the 
entrance to the clinical trial. 
     We are planning to supply at a 
cheap price the artificial retina OUReP to 
the blind people all over the world. “No 
one left behind in the world”, as stated in 
the Sustainable Development Goals 
(SDGs) in the United Nations, is a key 
concept in this project. Retinal prosthesis 
with multielectrode array system has 
been sold at an expensive price in the 
United State and Europe, and this cost is 
not affordable in most people in the 
world including Japan. Japan has 
maintained national health insurance 
system since 1961 to provide medical 
services at low cost to all people. 
Recently, however, expensive new drugs 
and medical devices which have been 
included in the health insurance system 
put a heavy burden on the finance of the 
system. A new device at low cost will be 
provided by “industrial innovation” 
(SDG 9), and thus, “people’s good health 
and well-being” (SDG 3) will be 
maintained at equal opportunity all over 
the world, leading to “reduced 
inequalities in the world” (SDG 10). “As 
partnerships for the goals” (SDG 17), we 
are working as a multidisciplinary team 
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